Benzbromarone stabilizes ΔF508 CFTR at the cell surface

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Cystic fibrosis is caused by mutations in the CFTR gene, leading to misfolded CFTR protein.
• The most common mutation, ΔF508, results in protein misfolding and degradation, preventing proper chloride channel function.
• Current therapies offer limited efficacy, highlighting the need for novel treatment strategies.

Purpose of the Study:

• To investigate the potential of small molecules to correct ΔF508 CFTR protein misfolding and improve its stability.
• To identify compounds that can directly bind to and stabilize the ΔF508 CFTR protein at the cell surface.

Main Methods:

• Utilized benzbromarone, a small molecule, to target the transmembrane domains of CFTR.
• Assessed the effect of benzbromarone on ΔF508 CFTR protein maturation and stability using cell surface assays.
• Compared the stabilization effect of benzbromarone with traditional low-temperature rescue methods.

Main Results:

• Direct binding of benzbromarone to CFTR transmembrane domains promoted protein maturation.
• Benzbromarone significantly stabilized ΔF508 CFTR at the cell surface, increasing its half-life approximately 10-fold compared to low-temperature rescue.
• This stabilization suggests improved protein function and potential therapeutic benefit.

Conclusions:

• Benzbromarone demonstrates significant potential in rescuing and stabilizing the ΔF508 CFTR protein.
• Targeting CFTR protein stabilization with small molecules represents a promising therapeutic avenue for cystic fibrosis.
• Further research into small molecule modulators could lead to effective cystic fibrosis treatments.